drugset
drugset / Trial / NCT03826719

Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers

NCT03826719 ↗

Phase 1/2 Completed 100 enrolled SK Chemicals Co., Ltd.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study assesses safety, tolerability and immunogenicity of NBP607QIV to Agrippal which are indicated for active immunization for the prevention of influenza disease.

Timeline

Start
2014-02-17
Primary completion
2014-03-28
Completion
2014-03-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Agrippal Vaccine 0.5 ml Intramuscular
Subject NBP607-QIV Vaccine 0.5 ml Intramuscular

Indications

influenza